Mc38 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mc38 cell lines/product/ATCC
Average 86 stars, based on 7 article reviews
Price from $9.99 to $1999.99
1) Product Images from "A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses"
Article Title: A nanoparticle vaccine that targets neoantigen peptides to lymphoid tissues elicits robust antitumor T cell responses
Journal: NPJ Vaccines
Figure Legend Snippet: The impact of KRAS peptide–Lpx on tumor growth was completely dependent on CD8 + T cells while depletion of CD4 + T cells had no impact. a , b Depletion of CD4 + or CD8 + T cells before and during the growth of MC38-G12D tumors (solid arrow; every 2–3 days) in mice immunized with the naked peptide G12D 1–23 and CpG ( a ) or with G12D 1–23 –Lpx starting on day −8 (dashed arrow) ( b ). Significance was determined using two-way ANOVA (**** p
Techniques Used: Mouse Assay
Figure Legend Snippet: Tumors respond to the peptide–lipoplex vaccine by upregulating MHC class I and II molecules and PD-L1. a MHC class I (H2D b ) expression on MC38-G12D cells before tumor implantation. b , c MHC class I and MHC class II expression on MC38-G12D tumors or CD11b + myeloid cells from mice immunized with lipoplex (Lpx) control or G12D 1–23 peptide–lipoplex. d PD-L1 expression analyzed by flow cytometric analysis on MC38-G12D tumors and tumor-infiltrating myeloid cells in mice immunized with Lpx control or G12D 1–23 peptide–Lpx. Significance was determined using a one-sided Student’s t- test ( b – d ). (* p
Techniques Used: Expressing, Tumor Implantation, Mouse Assay
Figure Legend Snippet: Therapeutic peptide–lipoplex vaccination in combination with checkpoint inhibition elicits potent anti-tumor responses with exhausted TILs. a Detection of mutant Adpgk-specific CD8 + TILs in mice immunized with Neo-Lpx using an MHC class I dextramer specific for Adgk. b , c TILs specific or not for Adpgk using dextramer staining were analyzed for PD-1 and Tim3 expression ( b ) and CTLA4 and Lag3 expression ( c ). d Mutant Adpgk and Copg1 27-mers with G12D 1–23 peptide were formulated lipoplexes (Neo-Lpx) to immunize mice with MC38-G12D tumors 5 days after implantation (solid arrows). Mice were immunized and/or treated with PD-1 antibody or isotype control after randomization on day 14 (dashed arrows). e Tumor growth curves of individual mice from ( d ). Significance was determined using two-way ANOVA (**** p
Techniques Used: Inhibition, Mutagenesis, Mouse Assay, Staining, Expressing
Figure Legend Snippet: Vaccination with neoantigen peptide–Lpx generates peptide-specific effector CD4 + and CD8 + T cells. a Tumors and spleens from MC38-G12D tumor-bearing mice that were immunized with the G12D 1-23 -Lpx were analyzed on day 25. Analysis of CD8 + and CD4 + T cell infiltrating the tumors determined by the CD8/CD4 ratio. b IFN-γ ELISpot of splenocytes re-stimulated with the immunizing G12D 1–23 or WT peptide in tumor-bearing mice. c Intracellular cytokine staining of CD4 + and CD8 + T cells from spleens of MC38-G12D tumor-bearing mice after G12D 1–23 peptide re-stimulation . d , e Expression of PD-1 and Ki67 based on IFN-γ production from G12D 1–23 -stimulated CD4 + and CD8 + T cells gated from c . (** p
Techniques Used: Mouse Assay, Enzyme-linked Immunospot, Staining, Expressing
Figure Legend Snippet: Vaccination with neoantigen peptide–lipoplexes enhances CD8 + T cell responses and controls tumor growth in syngeneic tumors expressing mutant KRAS. a Growth of MC38-G12D tumors in C57Bl/6 mice immunized with empty liposomes and CpG control (+Lpx Ctrl), G12D 1–23 peptide and CpG (+G12D 1–23 ), or with G12D 1–23 in lipoplexes (+G12D 1–23 –Lpx) starting 10 days before implantation and every 7 days for 3 weeks (dashed arrows) (n = 5–10). b Growth of MC38-WT tumors in mice immunized with G12D 1–23 –Lpx as indicated by the dashed arrows ( n = 5). c Growth of MC38-WT and MC38-G12D tumors in mice immunized with G12D 1–23 –Lpx starting at randomization on days 8 and 7 days later (arrows) (n = 7–9). d Mice were immunized with the mutant Adpgk and Copg1 27-mer peptides and CpG (top) and with the 27-mer complexed Lpx twice, one week apart. Splenocytes were stimulated with the immunizing peptide and the 9-mer that stimulates CD8 + T cells ( n = 3). e Growth curves of mice immunized with the Adpgk, Copg1, and G12D 1–23 SLP–Lpx (Neo-Lpx) at the indicated time points (arrows) ( n = 9–11). f Tumor-infiltrating Foxp3 + CD4 + regulatory T cells were quantified by intranuclear staining on day 23. g CT26 tumor growth in mice immunized with empty Lpx control or G12D 1–23 –Lpx on the day of randomization and 1 week later ( n = 9–10). h Naive Balb/c mice were s.c. immunized with the indicated neoantigen peptides in the naked form (top) or with Lpx (bottom) once weekly for 2 weeks and an IFN-γ ELISpot was performed to detect reactivity to the immunizing SLP or 9-mer corresponding to the predicted CD8 + T cell epitope. i Randomized CT26 tumors were immunized with empty Lpx control, CpG, and neoantigen (Neo) peptides (KRAS-G12D 1–23 , Tmem87a G63R 27-mer, and Slc4a3 T373I 27-mer), or neoantigen peptide–lipoplexes (Neo-Lpx). Mice immunized twice after randomization ( n = 7–11). Significance was determined using two-way ANOVA and one-sided Student’s t -test (**** p
Techniques Used: Expressing, Mutagenesis, Mouse Assay, Staining, Enzyme-linked Immunospot
2) Product Images from "IL-9/STAT3/fatty acid oxidation–mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity"
Article Title: IL-9/STAT3/fatty acid oxidation–mediated lipid peroxidation contributes to Tc9 cell longevity and enhanced antitumor activity
Journal: The Journal of Clinical Investigation
Figure Legend Snippet: Persistence of adoptively transferred CD8 + T cells in the TME is negatively correlated with their lipid peroxidation. ( A and B ) Thy1.1 + Pmel-1 Tc1 or Tc9 cells were i.v. injected into Thy1.2 + B6 mice bearing 10-day s.c. B16 tumors with adjuvant treatments (CTX, dendritic cells, and rhIL-2). Tumor growth curve ( n = 5), Thy1.1 + percentages in CD8 + T cells, and Thy1.1 + CD8 + T cell numbers in tumors on day 45 after tumor injection ( n = 8). ( C and D ) GSEA of indicated gene sets on day 24 after tumor injection. GO, Gene Ontology; NES, normalized enrichment score. ( E ) Lipid content (BODIPY 495/503 staining), ( F ) total ROS level (CM-H 2 DCFDA staining), ( G ) lipid ROS, and ( H ) PD-1 and LAG-3 expression of transferred Tc1 and Tc9 cells on day 45 after tumor injection ( n = 10, two pooled independent experiments). ( I ) Tumor-infiltrating Tc9 cells were divided into PD-1 + and PD-1 – groups and analyzed for the level of lipid ROS ( n = 10). ( J and K ) Thy1.1 + Pmel-1 Tc1 or Tc9 cells were i.v. injected into Thy1.2 + B6 mice bearing 10-day MC38-gp100 tumors with adjuvant treatments. Shown are Thy1.1 + percentages in CD8 + T cells, Thy1.1 + CD8 + T cell numbers, and relative lipid ROS levels of Tc1 and Tc9 cells in tumors on day 40 after tumor injection ( n = 6). ( L and M ) Thy1.1 + Pmel-1 Tc1 or Tc9 cells were i.v. injected into Thy1.2 + B6 mice bearing 12-day lung metastatic B16 tumors. Shown are Thy1.1 + percentages in CD8 + T cells, Thy1.1 + CD8 + T cell numbers, and relative lipid ROS levels of Tc1 and Tc9 cells in tumors on day 17 after tumor injection ( n = 6). Data are presented as mean ± SEM. Tumor-infiltrating Thy1.1 + CD8 + T cell number was normalized to 100 mg tumor tissue. * P
Techniques Used: Injection, Mouse Assay, Staining, Expressing
3) Product Images from "TIGIT predominantly regulates the immune response via regulatory T cells"
Article Title: TIGIT predominantly regulates the immune response via regulatory T cells
Journal: The Journal of Clinical Investigation
Figure Legend Snippet: TIGIT restrains antitumor immune responses. ( A ) Growth of B16F10 melanoma or MC38 colon carcinoma in WT or Tigit –/– mice ( n = 5–6). Data are representative of 3 independent experiments. *** P
Techniques Used: Mouse Assay
4) Product Images from "HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties"
Article Title: HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
Figure Legend Snippet: Antitumor response of HX008 in HuGEMM Model. Human PD-1 knock-in mice were subcutaneously implanted with MC38 cells (1 × 10 6 per mouse) and were randomized into treatment groups after mean tumor volume reached 134 mm 3 . Single i.v. administration of HX008 (5 mg/kg or 10 mg/kg, n = 8/group) or positive control pembrolizumab (10 mg/kg, n = 8) and isotype control (10 mg/kg, n = 8) were performed twice weekly as indicated, six times in total. Tumor volume was measured twice a week and mice were euthanized at maximum allowed tumor burden. (a) tumor growth curves. (b) group mean tumor volume measured on Day 13 post dose. (c) individual tumor growth curves in each treatment group. The number of total free mice per group was indicated. (d) Body weight of HuGEMM MC38 bearing mice during the treatment. For comparisons between groups in the study, we used one-way ANOVA with the Dunn-Sidak post hoc test. Data were shown as SEM of 8 mice per group; ***, P
Techniques Used: Knock-In, Mouse Assay, Positive Control